Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
Operating Status
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Aquinox Pharmaceuticals
Aquinox Pharmaceuticals develops drugs to treat inflammation, pain, and blood cancers.
Sector
Subsector
Keywords
Location
total rounds
total raised
Cyclis Pharmaceuticals
Cyclis Pharmaceuticals is a biopharmaceutical company.
Sector
Subsector
Keywords
Location
total rounds
total raised
Trio Pharmaceuticals, Inc.
Trio Pharmaceuticals develops dual-action drugs for immunogenic tumors.
Sector
Subsector
Location
total rounds
total raised
Tetherex Pharmaceuticals
Tetherex Pharmaceuticals Corp is a biopharmaceutical company developing drugs to treat inflammation, thrombosis and tumor metastasis.
Sector
Subsector
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Astellas Pharma
announced date
price
Financials
Funding Rounds5
Number of Funding Rounds
Money Raised
Their latest funding was raised on 18.11.2013. Their latest investor Landesbank Baden Wurttemberg. Their latest round Series E
MIG
MIG is a leading German VC investor focused on early to mid-stage technology and life science companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Future Capital
Future Capital invests in life sciences, chemistry, nanotechnology, and material sciences.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
ATS Beteiligungsverwaltung
ATS Beteiligungsverwaltung GmbH, based in Munich, is a company that weaves together a diverse portfolio of investments.
Sector
Subsector
Keywords
count Of Investments
count Of Exists
MIG
MIG is a leading German VC investor focused on early to mid-stage technology and life science companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Future Capital
Future Capital invests in life sciences, chemistry, nanotechnology, and material sciences.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Ingro Finanz AG
Ingro Finance AG specializes in purchasing, managing, and selling investments, including life science.
Sector
Subsector
Location
count Of Investments
count Of Exists
VI Partners
VI Partners AG is a Swiss venture capital firm supporting innovative technology and healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
ATS Beteiligungsverwaltung
ATS Beteiligungsverwaltung GmbH, based in Munich, is a company that weaves together a diverse portfolio of investments.
Sector
Subsector
Keywords
count Of Investments
count Of Exists
Co-Investors
Investors7
Number of lead investors
Number of investors
Landesbank Baden Wurttemberg
LBBW Landesbank Baden-Wurttemberg is a large German bank with a regional focus.
Sector
Subsector
Location
count Of Investments
count Of Exists
Ingro Finanz AG
Ingro Finance AG specializes in purchasing, managing, and selling investments, including life science.
Sector
Subsector
Location
count Of Investments
count Of Exists
VI Partners
VI Partners AG is a Swiss venture capital firm supporting innovative technology and healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders2
Dirk Sebastian
Mr. Sebastian has over 15 years of executive experience in drug discovery operations, business development and financial management. Prior to co-founding Ganymed, he served as head of operations of Mermaid Pharmaceutical GmbH, taking that company from early start-up phase through the capital formation and growth to more than 70 employees. He also co-founded and directed Nigeons GmbH, a company that provided operational and translocation consulting services to pharmaceutical and biotechnology companies. Mr. Sebastian obtained his degree in engineering and business administration from the Universities of Siegen and Hamburg, Germany.
current job
organization founded
Dirk Sebastian
Christoph Huber
After his studies at Medical School of the Leopold Franzens University in Innsbruck,Christoph Huber gained experience as a health professional of internal medicine and received his Ph.D. Several research scientist visits (Dept. Tumor Biology of Karolinska Institute, Stockholm, Wallenberg Laboratorium, Dept. Immunology of Uppsala University) were followed by an education in clinical bone marrow transplantation at the Fred Hutchinson Cancer Research Center, Seattle. Back in Innsbruck, Huber headed the bone marrow transplantation section of the Department of Internal Medicine, eventually becoming Professor of Clinical Immunobiology. Huber is Emeritus Professor of Medicine at the Medical School of the Johannes Gutenberg University in Mainz, co-founder and board member of the Translational Oncology research organization and co-founder and Head of Supervisory Board at the Cluster for individualized immune intervention (CI-3). Huber also co-founded the biopharmaceutical companies Ganymed Pharmaceuticals and BioNTech and serves on both of their boards. Huber is a member of numerous scientific committees, in particular the international Association of Cancer Immunotherapy (CIMT), which he co-founded and chairs. Huber is the author of more than 250 publications, among them various articles in “Nature”, “Nature Immunology”, “Immunity”, and the “Journal of Experimental Medicine”.
current job
organization founded
Christoph Huber
